Summary of Key Financial Results
|
3 Months
|
3 Months
|
12 Months
|
12 Months
|
|
ended Dec
|
ended Dec
|
ended Dec
|
ended Dec
|
|
Canadian dollars
|
31 2020
|
31 2019
|
31 2020
|
31 2019
|
|
$
|
$
|
$
|
$
|
|
Revenues (‘000s)
|
2,518
|
2,510
|
8,017
|
9,582
|
|
Gross profit before fair value adjustments (‘000s)
|
402
|
1,048
|
1,481
|
2,436
|
|
General and administrative costs (‘000s)
|
5,157
|
6,260
|
20,877
|
20,525
|
|
Net loss (‘000s)
|
(2,374)
|
(8,235)
|
(24,039)
|
(36,378)
|
|
Adjusted EBITDA (1) (‘000s)
|
(4,335)
|
(6,342)
|
(18,762)
|
(24,504)
|
|
Net loss per share (basic and diluted)
|
(0.01)
|
(0.06)
|
(0.20)
|
(0.36)
|
|
Weighted average shares outstanding (‘000s)
|
130,292
|
115,399
|
120,294
|
101,966
|
|
(1)
|
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization or in this case loss) is a non-International Financial Reporting Standards (“IFRS“) measure calculated as net loss before tax as reported under IFRS and adding back share-based compensation expense, transaction fees, unrealized gain on changes in fair value of biological assets, depreciation and non-recurring items. Refer to the “Non-IFRS Measures” note below for further information and the Company’s MD&A for a reconciliation.
|
Q4 2020 highlights
- Total revenues in Q4 2020 reached $2.5 million, reflecting sequential quarter-on-quarter growth of 31%, as patient consultations at Company-owned clinics returned to pre COVID-19 levels and Medical Cannabis Product revenues more than doubled over Q3 2020. Fourth quarter revenue growth was flat year-over-year, due to lower Health Services and Wellbeing Product revenues, offset by Medical Cannabis Product sales of $234,000.
- The Company continues to benefit from favourable market conditions and vertically integrated operations, generating gross margins of 92% on its Medical Cannabis Product segment in Q4 2020.
- The Company continues to prudently manage expenses, with fourth quarter selling, general and administrative (“SG&A“) expenses declining 22% year-over-year. Following cost reductions implemented earlier in the year, Q4 2020 SG&A expenses of $5.9 million increased 3% sequentially from Q3 2020.
- On November 26, 2020, the Company completed a bought deal financing selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000.
- In December 2020, the Company announced that, following a directive by Colombia’s federal government, Colombia became one of the first countries to extend national health insurance to include medical cannabis as a first line therapy for patients. As a result, Medical Cannabis Product sales increased significantly starting December 2020, contributing to sequential quarter-on-quarter revenue growth of 113% in Q4 2020.
- In December 2020, the Company initiated its satellite clinic expansion strategy, opening its first location in Medellin, Colombia’s 2nd largest city.
- As of December 31, 2020, the Company had cash of $21.6 million and working capital of $29.1 million.
2020 Annual Highlights
- During the year, the Company commenced medical cannabis sales in Colombia, Peru, and the UK, becoming the first Company to sell medical cannabis magistral preparations in Colombia and Peru, and medical cannabis flower in Scotland.
- In 2020, the Company launched its Zerenia medical clinic strategy, opening its flagship Bogota, Colombia location in May 2020 and first satellite location in Medellin, Colombia in December 2020.
- In September 2020, Khiron was declared a National Strategic Project by the government of Colombia, simplifying and accelerating regulatory processes for the Company in the country.
- In 2020, the Company filled approximately 5,700 prescriptions in Latin America, generating total Medical Cannabis Product sales of $370,000, including $234,000 in the fourth quarter.
- In total, the Company generated total revenues of $8.0 million and gross profit of $1.5 million in 2020. While COVID-19 had a negative impact on Health Services revenues and margins, particularly earlier in the year, the Company was able to largely offset declines through prudent expense management.
Subsequent events and 2021 highlights
- With the start of medical cannabis insurance coverage in Colombia in December 2020, the Company filled approximately 135% more prescriptions in Q1 2021 than in all of 2020. Additionally, in Q1 2021, 60% of medical cannabis prescriptions filled in Colombia were fully covered by insurance.
- Returning medical cannabis patient volumes continue to improve, increasing from 20-25% of total monthly patients in Q3 2020, to nearly 50% in Q1 2021.
- Between Q2 2020 and Q1 2021, filled prescriptions per Health Care Professional (HCP) increased from 0.9/day to 4.5/day at Khiron’s wholly-owned clinics.
- Following the initial success of the Medellin satellite clinic, the Company opened three additional satellite clinics in Colombia in Q1 2021 with plans to open another three locations by June 2021. Additionally, the Company plans to deploy its Zerenia™ medical cannabis clinic and telehealth strategy in Mexico, building on the success of its vertical integration strategy in Colombia.
- Khiron Academy, the Company’s medical cannabis e-learning certification, has been completed by hundreds of physicians across Latin America and Europe and was accredited for UK Continuing Professional Development.
- In March 2021, the Company successfully exported its Colombian-registered cannabis strains, in the form of live clones, from Colombia to Europe. This represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets as the Company executes on its asset-light growth strategy in the United Kingdom and Germany.
- In March 2021, Khiron commenced sales in Germany with the successful delivery of EU-GMP medical cannabis products. Khiron 1/14 (High CBD flower) has been used to treat indications such as anxiety, substance-use disorder and migraines.
- In April 2021, the Company introduced Khiron 1/14 (High CBD flower) in the UK. Prescribing specialists will also be able to prescribe smaller quantities of Khiron flower products in 5-gram jars.
Management commentary
“2020 marked a turning point for the Company as we transitioned from start-up mode to the sales execution phase of our strategy. Despite the many challenges brought on by the global pandemic, our team persevered and had many significant accomplishments in 2020, including first medical cannabis sales in Colombia, Peru and UK, along with Germany in March 2021, the launch of our telemedicine platform and Zerenia clinics, and expanded patient access through medical cannabis insurance coverage in Colombia. As we progress through 2021, I remain very optimistic about the year ahead. We are very well positioned to leverage the knowledge, experience and infrastructure developed over the last year, to accelerate growth both at home and abroad,” comments Alvaro Torres, Chief Executive Officer and Director of the Company.
Non-IFRS Measures
This press release may contain references to “Adjusted EBITDA”, “Gross Profit” and “Gross Margin”, which are non-IFRS financial measures. The Company defines adjusted EBITDA as net loss before tax as reported under IFRS and adding back share-based compensation expense, transaction fees, unrealized gain on changes in fair value of biological assets, depreciation and non-recurring items and is a measure of the Company’s overall financial performance and is used as an alternative to earnings or net income in some circumstances. This performance measure is employed by management to assess the Company’s operating and financial performance and to assist in business decision-making. This measure does not have any standardized meaning according to IFRS and therefore may not be comparable to similar measures presented by other companies. Gross Margin is the difference between revenue and cost of goods sold divided by revenue and is expressed as a percentage. Management believes that these measures provide useful information as they provide investors with added insight into Khiron’s financial performance. Readers are cautioned that such non-IFRS measures may not be appropriate for any other purpose. Non-IFRS measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information, including without limitation, statements relating to the Company’s anticipated sales and operations in Brazil and Mexico, the opening of additional satellite clinics and locations in Colombia, the effects of the Company’s first shipment of medical cannabis live plant material to Europe from Colombia, the ability of specialists to prescribe smaller quantities of medical cannabis flower products, the Company’s growth expectations and strategic plans. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable).
Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statements have been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate, including without limitation those regarding the continuance of favourable market conditions in the Company’s current markets and the anticipated demand for medical cannabis in the markets in which the Company operates or is contemplating operations.
Readers are cautioned that the above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include the risk factors discussed in Khiron’s most recently filed annual information form, which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof.
Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
(This information is primarily sourced from Khiron. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here). |
